Ocular Surface Disease
An Introduction to Ocular Surface Disease
Ocular surface disease is a prevalent condition, and with the increasing use of screens and monitors, this trend is likely to continue. Treatment options include artificial tears and gels, short courses of corticosteroids and prescription drugs cyclosporine 0.05% and lifitegrast 5%. Several devices have recently been introduced that help to relieve meibomian gland congestion and offer an alternative treatment.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Ocular Surface Disease Content
The Role of Biofilms in Pathology of the Ocular Surface
touchREVIEWS in Ophthalmology. 2021;15(1):12–14. DOI: https://doi.org/10.17925/OPHT.2021.15.1.12
Over the past few years, we have witnessed an increasing awareness of the importance of treating ocular surface disease (OSD). Diagnoses such as dry eye and blepharitis, which were historically under-appreciated, now command attention from the ophthalmologist and investment from the ocular pharmaceutical industry. Proper treatment of the ocular surface is paramount to the health […]
Tear Film Biomarkers in Dry Eye Disease
US Ophthalmic Review. 2020;13(2):68-72 DOI: https://doi.org/10.17925/USOR.2020.13.2.68
Dry eye disease is a chronic condition that affects the corneal surface, and is clinically characterized by loss of tear volume and increased evaporation of tears.1,2 The definition of dry eye disease has evolved since it was first recognized over 30 years ago, with advanced research resulting in a better understanding of the disease pathophysiology.3 The official […]
Jennifer Loh: ASCRS 2020 – A Novel, Targeted, Open Eye, Thermal Therapy for Treatment of Dry Eye
Jennifer Loh (South Florida Vision Associates, Fort Lauderdale, Florida, USA) discusses unmet needs in the treatment of dry eye, and gives an overview of the TearCare system and the efficacy and safety findings of the OLYMPIA clinical trial. Questions: 1. What are the major unmet needs in the treatment of dry eye? (0:12) 2. Could […]
Hot Topics – How to minimise eye drop burden postoperatively
Cynthia Matossian discusses the latest technological and pharmaceutical advancements that are easing the burden of administering eye drops, both for patients and their caregivers.
Hot Topics – Treatment options for meibomian gland dysfunction include intense pulsed light, what is it?
Cynthia Matossian discusses intense pulsed light (IPL), a new treatment for meibomian gland dysfunction, which is one of the causes of dry eye disease.
Hot Topics – What procedures and tools are used to treat meibomian gland dysfunction?
Cynthia Matossian discusses the procedures and tools that are currently available to treat dry eye disease associated with meibomian gland dysfunction, including LipiFlow® from Johnson and Johnson, TearCare® (Sight Sciences), and EyeLocks from Alcon.
Hot Topics – What pharmaceutical products beat dry eye disease?
Cynthia Matossian discusses some of the new pharmaceutical products that are available for dry eye disease, including Restasis®, XiidraTM (lifitegrast), CequaTM (cyclosporine), and Klarity-C Drops® that are available on prescription when dry eye disease patients present with inflammation.
Dry Eye – Can You Cry?
European Ophthalmic Review. 2019;13(2):81–6
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!